displayed an elevated level of cell death induced by gemcitabine. Accordingly, knockdown of GAS5 in bladder cancer cells by small interfering RNA conferred tolerance to gemcitabine-induced cytotoxicity ( Figure 3C, 3D) . DCK is the rate-limiting enzyme responsible for conversion of gemcitabine to active antimetabolite. By knocking down GAS5 in bladder cancer cells, we experimentally confirmed that GAS5 regulates DCK expression. Furthermore, we revealed that proapoptotic function of GAS5 was correlated with promoting HuR nuclear export and the biological consequence of deoxycytidine kinase expression (Fig. 2) .
INTRODUCTION AND OBJECTIVES: Our recently published results revealed that NOTCH2 is an oncogene that drives bladder cancer (BCa) progression. To test whether NOTCH2 can promote BCa development, we have established a constitutively active NOTCH2 intracellular domain (N2ICD) mouse model. Previous TCGA data showed that NOTCH2 expression and copy number gain are enriched in basal tumors.
METHODS: We have created lentiviral constructs based on the FUGW vector containing the N2ICD transgene, driven by either uroplakin-2 (Upk2, to induce luminal tumors) or cytokeratin-5 (Krt5, to induce basal tumors). These constructs also include intraribosomal entry sequence (IRES) followed by the firefly luciferase gene. Lentiviral particles were inocluted by ultra-sound guided injections into the subepithelial space of the bladder wall. Mice were treated with the bladder specific carcinogen BBN (0.05%, in drinking water) for 12 weeks. We have also tested the metastatic potential of NOTCH2 mutants (A2025E and Q2223X) over-expressed cell lines in vivo using the zebrafish embryo model. Each wild-type, NOTCH2 mutants (A2025E and Q2223X), N2ICD over-expressed RT4 or RT112 cell lines, and NOTCH2 knock-down UC13 cell lines were injected to zebrafish embryo. After 3 days, the number of metastases were counted.
RESULTS: Luciferase activity was observed in the bladder of some mice 20 weeks into the experiment: 2 cases in the empty vector control group (2/15, 13.3%), 6 cases in the Upk2 group (6/15, 40%), and 5 cases in Krt5 group (5/15, 33.3%). The tumors in both Upk2 and Krt5 group showed not only urothelial but also squamous cell carcinoma features. Moreover, in both Upk2 and Krt5 group, tumorigenesis was observed in 20 weeks after BBN while tumorigenesis in control group was observed in 26 weeks. In the zebrafish model, the number of metastasis were increased in the N2ICD over-expressed groups compared to the wild-type and mutant lines, while the metastasis were decreased in NOTCH2 knock-down UC13 line.
CONCLUSIONS: Our results suggest that the over-expression of N2ICD in the bladder wall could accelerate tumor development and possibly lead to more malignant phenotypes. Moreover, over-expression of N2ICD promotes metastatic potential.
Source of Funding: none

MP65-06 THE URINARY MICROBIOME DIFFERS BETWEEN BLADDER CANCER AND CONTROL CASES
Hai Bi*, Jiarui Li, Chuan Song, Ya Tian, Tingting Liu, Chen Chen, Lulin Ma, Yuanyuan Zhang, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: There are plenty of evidence that the human microbiota influence cancer susceptibility. Chronic inflammation of urinary tract infection is a known risk factor of bladder cancer. But, until now, the correlation between urinary microbiota and bladder cancer is unclear. In this study, we characterize and analysis the composition of urinary microbiota from bladder cancer and control cases.
METHODS: We used the midstream urine as the samples. All the patients didn't take antibiotics at the time of sampling. Comprehensive characterization and comparison of the urine microbiota from bladder cancer cases (n¼29) and control (n¼26) was performed. The amplicon of partial 16s rDNA (V3-V4) was sequenced using the Illumina MiSeq platform. The statistical significance of differences among cancer cases and control was tested with Wilcoxon rank-sum test.
RESULTS: The sequencing data indicated that Firmicutes, Actinobacteria, Proteobacteria, Bacteroidetes are the predominant phylum-like groups. Among them, Proteobacteria was more represented in the bladder cancer cases (p¼ 0.003090). Significant difference (p¼ 0.003086) in the microbiota composition between two groups were observed at the genus level. Among genera, Corynebacterium spp. was the dominant genus in the bladder cancer groups, but there was no statistic difference in two groups. While Staphylococcus spp. was the dominant genus in control. In 5 highest abundance of genus, Lactobacillus spp. and Streptococcus spp. were significantly decreased in cancer group (p<0.01). In 73 genera with percentage >¼0.01, 21 genera existed in all samples. The abundance of Lactobacillus spp., Streptococcus spp., Veillonella spp., Bifidobacterium spp. significantly decreased in cancer group, and only Actinomyces spp. increased in cancer group.
CONCLUSIONS: Variations in microbiota may be a new risk factor for a variety of cancers. Our study with a small sample size showed an enrichment of Actinomyces spp. in urines from patients with bladder cancer. Urinary microbiota may play an important role in the bladder cancer.
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